Effectiveness of vaccination for human papilloma virus infection causing cervical cancer in patients with lupus

Human papilloma virus infection in SLE: prevalence and response to catch up vaccination with quadrivalent vaccine - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105586

Enrollment

100

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M32- Systemic lupus erythematosus (SLE)

Interventions

Intervention1: Gardasil: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant (NA), MSD Pharmaceuticals in 100 patients of SLE Control Intervention1: Gardasil: Human Papill

Eligibility

Inclusion criteria

Inclusion criteria: Adults patients of SLE who satisfy the ACR 2019 criteria for SLE

Exclusion criteria

Exclusion criteria: Prior vaccination with HPV vaccine ,History of cervical cancer

Design outcomes

Primary

Measure	Time frame
IgG antibodies to HPV by ELISA in patient serumTimepoint: 1 year post 1st dose of vaccination	—

Secondary

Measure	Time frame
In the subgroup positive for HPV DNA in cervical secretion at baseline: 1. Paired HPV DNA quantification in cervical secretion at baseline and 1 year 2. Paired pap smear for cervical dysplasia at baseline and 1 years.Timepoint: 1 year post first dose of vaccine	—

Countries

India

Contacts

Public ContactRudrarpan Chatterjee

Sanjay Gandhi Postgraduate Institute of Medical Sciences , Lucknow

rudi.gmc2009@gmail.com05222494284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026